Initial treatment with intravenous immunoglobulin (IVIG) plus infliximab lessens the need for additional therapy in Kawasaki disease (KD) patients presenting with coronary artery lesions (CALs), a recent study has shown.
Low-density lipoprotein cholesterol (LDL-C) levels remained high in many patients with stable or acute coronary heart disease (CHD) in Asia, despite having a very high risk of recurrent cardiovascular (CV) events, indicating that the use of lipid-lowering therapies and lipid monitoring were inadequate.
The survival benefits conferred by blood pressure (BP) and lipid-lowering medications persist even after more than a decade following the end of the original trial, according to results from the ASCOT* Legacy study.
More patients initiating or escalating anti-hypertensive treatment achieved their blood pressure (BP) goals when taking a once-daily pill containing low doses of three antihypertensive medications (telmisartan, amlodipine, and chlorthalidone) compared with those on usual care, according to the TRIUMPH* study conducted in Sri Lanka.
Nearly half of atrial fibrillation (AF) patients on vitamin K antagonist (VKA) with prior time in therapeutic range (TTR) ≥70 percent had TTR <70 percent during the following year, reports a recent study. Additionally, there is limited long-term prognostic value for prior TTR ≥70 percent.
Isolated or combined blood pressure (BP) elevations identified by office or ambulatory measurements are associated with a greater risk of new-onset metabolic syndrome (MetS), suggests a recent study. On the other hand, only white-coat hypertension (WCH) is linked to an increased risk of incident MetS whenever BP phenotypes are identified by office or home measurement.
The outcome for patients experiencing out-of-hospital sudden cardiac arrest (OSCA) remains very poor in Malaysia. Local data shows that return of spontaneous circulation in OSCA patients stands at 17.4 percent, while survival to ward is a mere 4.3 percent. [Med J Malaysia 2008; 63:4–8]
A trial assessing the implantable CardioFit® device designed to stimulate the parasympathetic nervous system in heart failure patients failed to meet its primary endpoints – reducing the rate of hospitalization due to heart failure or death by any cause.